US.RVTY · Revvity

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.050190176947247,
        "turnoverUsdM": 162.4296764,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.RVTY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 113.5622,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.1,
      "take_profit_price": 126.987,
      "target_multiplier": 1.6,
      "technical_strength": 1.22,
      "take_profit_percent": 5
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.100380353894494,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 52.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 48.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 124.2105,
    "ma50": 117.1246,
    "close": 120.94,
    "prevClose": 123.85,
    "avgVolume20": 1589793,
    "volumeRatio": 0.84,
    "changePercent": -2.35
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": -0.07637085688101419,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.8482502068425407,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.6598553992548043,
      "volat_points": 0,
      "day_range_pct": 0.019307094426988657,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 52.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 48,
        "contribution": 2.4
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 4.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 29.33,
        "contribution": 4.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 18,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 60,
        "contribution": 18
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 48.3,
    "details": [
      "基本面分析總分: 2.4/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 4.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 18/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.4,
      "資金流": 9.2,
      "市場環境": 4.4,
      "情緒分析": 6,
      "技術信號": 18,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 162.4296764,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 2.4,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.RVTY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.050190176947247,
          "atrPoints": 2,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142026577,
                "url": "https://finnhub.io/api/news?id=cb092d0177c73ef991e01bd2f9b86bc6b770d0cc8355a7025df5d92b2dc0bbcc",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788958626,
                "headline": "Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript"
              },
              {
                "id": 141394957,
                "url": "https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...",
                "category": "company",
                "datetime": 1788401656,
                "headline": "Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"
              },
              {
                "id": 141376585,
                "url": "https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...",
                "category": "company",
                "datetime": 1788350787,
                "headline": "Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"
              },
              {
                "id": 141374543,
                "url": "https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489",
                "image": "",
                "source": "Fintel",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788331013,
                "headline": "RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"
              },
              {
                "id": 141370258,
                "url": "https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1788282002,
                "headline": "What Makes Revvity (RVTY) a New Buy Stock"
              },
              {
                "id": 141202718,
                "url": "https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Diagnostics surged 11% organically as AI-driven demand accelerated.",
                "category": "company",
                "datetime": 1786468489,
                "headline": "Revvity (RVTY) Q2 2026 Earnings Call Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142025419,
                "url": "https://finnhub.io/api/news?id=26ba77f1d5d5d1d933db3ca05680140c3536502285a122c8a8b36cdf9f7d1322",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Let's have a look at the S&P500 gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1788964501,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 142026577,
                "url": "https://finnhub.io/api/news?id=cb092d0177c73ef991e01bd2f9b86bc6b770d0cc8355a7025df5d92b2dc0bbcc",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788958626,
                "headline": "Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript"
              },
              {
                "id": 142007727,
                "url": "https://finnhub.io/api/news?id=c1105d1e4e608643a2f4b83f95153adcb96bcc32f5073d0146317266dabca956",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin",
                "category": "company",
                "datetime": 1788948000,
                "headline": "Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery"
              },
              {
                "id": 142026253,
                "url": "https://finnhub.io/api/news?id=14a165ee3da6cf1e87cced8f93e5010791421eec4a891b5f0776077838aedbf3",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "UBS  analyst Doug Schenkel   assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.",
                "category": "company",
                "datetime": 1788947825,
                "headline": "UBS Assumes Revvity at Neutral, Raises Price Target to $140"
              },
              {
                "id": 142026254,
                "url": "https://finnhub.io/api/news?id=afa5a4ecb2479e8eee511d8473093253608857e03a715a73a0bd02872012e9a4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/09/Revvity-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.",
                "category": "company",
                "datetime": 1788946529,
                "headline": "Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition"
              },
              {
                "id": 142026255,
                "url": "https://finnhub.io/api/news?id=c0e3abf1a20772b3a6ef5ac36a02a5c40065dd69d9c3e39cefaa9ae53e03f69c",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": " The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other",
                "category": "company",
                "datetime": 1788934162,
                "headline": "Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases"
              },
              {
                "id": 141950366,
                "url": "https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro",
                "category": "company",
                "datetime": 1788878940,
                "headline": "Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"
              },
              {
                "id": 141425678,
                "url": "https://finnhub.io/api/news?id=f21a96053f253b59f417bd859feef95f766270d2e42bafa9937419d4bfaae0dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.",
                "category": "company",
                "datetime": 1788526140,
                "headline": "Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?"
              },
              {
                "id": 141420277,
                "url": "https://finnhub.io/api/news?id=8dff4283f6da452e92865d7101fd6ffa7f2bdc63d99febe33fac804fc18f8255",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher",
                "category": "company",
                "datetime": 1788518880,
                "headline": "Global Multiplex Assays Market 2026 Edition -  Consumables Dominate Multiplex Assays with 68% Market Share"
              },
              {
                "id": 141449917,
                "url": "https://finnhub.io/api/news?id=2f5b6dbf3c6e63d29e248fc2bc5f667c787cd9f592de5860faa835e287e2cc01",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Keybanc  analyst Paul Knight   maintains Revvity (NYSE:RVTY) with a Overweight and raises the price target from $125 to $165.",
                "category": "company",
                "datetime": 1788513490,
                "headline": "Keybanc Maintains Overweight on Revvity, Raises Price Target to $165"
              },
              {
                "id": 141394957,
                "url": "https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...",
                "category": "company",
                "datetime": 1788401656,
                "headline": "Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"
              },
              {
                "id": 141376585,
                "url": "https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...",
                "category": "company",
                "datetime": 1788350787,
                "headline": "Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"
              },
              {
                "id": 141374543,
                "url": "https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489",
                "image": "",
                "source": "Fintel",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788331013,
                "headline": "RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"
              },
              {
                "id": 141373643,
                "url": "https://finnhub.io/api/news?id=586a7b0273e63c068b81acc8775f2c6ac9290074de64940276220f0e54d8f76b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.",
                "category": "company",
                "datetime": 1788294620,
                "headline": "3 Hyped Up  Stocks We Find Risky"
              },
              {
                "id": 141370258,
                "url": "https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1788282002,
                "headline": "What Makes Revvity (RVTY) a New Buy Stock"
              },
              {
                "id": 141370259,
                "url": "https://finnhub.io/api/news?id=b4010c5290b28cfc54157cb45359ef75b9687f7cc7d4fb5bcd195348a5cc80a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo",
                "category": "company",
                "datetime": 1788280978,
                "headline": "Revvity Faces Growth Challenges Amid Rising Competition, RBC Says"
              },
              {
                "id": 141370883,
                "url": "https://finnhub.io/api/news?id=da5596eb573a2739f70a4762282fc12f50cb2181b295291669cc4c0452c29761",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "RBC Capital  analyst Dan Leonard   initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.",
                "category": "company",
                "datetime": 1788249814,
                "headline": "RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135"
              },
              {
                "id": 141361171,
                "url": "https://finnhub.io/api/news?id=40e9f3152f995605f71edc54cd5e8da04b68760f2b599ba43b23754aa3a6049b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "As UnitedHealth Group has outperformed relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects.",
                "category": "company",
                "datetime": 1788072487,
                "headline": "How Is UnitedHealth Group's Stock Performance Compared to Other Healthcare Plan Stocks?"
              },
              {
                "id": 141365522,
                "url": "https://finnhub.io/api/news?id=ee488ce9869916a3010f25f71ecd7d44f2eb7e982a65bdbcd691644f069d6b25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Investors need to pay close attention to RVTY stock based on the movements in the options market lately.",
                "category": "company",
                "datetime": 1787589000,
                "headline": "Is the Options Market Predicting a Spike in Revvity Stock?"
              },
              {
                "id": 141365523,
                "url": "https://finnhub.io/api/news?id=eb1cf6f63665ff456ed353f202bb56f9038280ac16ecae9524ce05ca57689b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1787585403,
                "headline": "Revvity Stock: Is Wall Street Bullish or Bearish?"
              },
              {
                "id": 141263724,
                "url": "https://finnhub.io/api/news?id=79817c6765abca477c158dde61718bc04fe3d602b4fecbff929b0a7fcd1bb05a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787252701,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141230562,
                "url": "https://finnhub.io/api/news?id=4d092ebe3aa6f83822c04a961bb022d30ba76830344f6c5fdbe0e95de91c9b2a",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1786857318,
                "headline": "Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside"
              },
              {
                "id": 141218677,
                "url": "https://finnhub.io/api/news?id=652224e6eaeca65523b7fcc05076da4b572b7f65213dd09624d1398b823f11df",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1786721166,
                "headline": "Danaher: 2027 Growth Reacceleration Should Drive Upside"
              },
              {
                "id": 141206709,
                "url": "https://finnhub.io/api/news?id=abf15460060e9d68def7ae24c3778a414925e71cb70a7b8f3956a47e4e500adc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.",
                "category": "company",
                "datetime": 1786629600,
                "headline": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs"
              },
              {
                "id": 141202717,
                "url": "https://finnhub.io/api/news?id=e2a2e352b10892b67e53ab7554bbeb3ba8baff2bbefdfaba1a2267691b1082dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to \"tangible signs of a more constructive spending environmen",
                "category": "company",
                "datetime": 1786587660,
                "headline": "The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call"
              },
              {
                "id": 141202718,
                "url": "https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Diagnostics surged 11% organically as AI-driven demand accelerated.",
                "category": "company",
                "datetime": 1786468489,
                "headline": "Revvity (RVTY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141202719,
                "url": "https://finnhub.io/api/news?id=c4fbd63bd68321a1fd0751f6671df4d112f0dbc162a5bed08991df064ba072e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:",
                "category": "company",
                "datetime": 1786449600,
                "headline": "Revvity to Present at Upcoming Investor Conferences"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 6,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 27,
            "discarded_article_count": 21
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(20.9%→9.8%)；跌縮量(近10日4日)；站上MA50；升放量(近10日2日)；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 1646760,
              "down_days": 7,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1782540,
              "avg_vol_20": 1583330,
              "avg_vol_30": 1646760,
              "range_pct_10": 0.0975690425004134,
              "range_pct_20": 0.15966595005787995,
              "range_pct_30": 0.20894658508351246,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.082452816439554,
              "dist_to_20d_high": 0.09067669172932333,
              "down_shrink_days": 4,
              "breakout_level_20d": 133,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4669568658488325
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.050190176947247,
              "turnoverUsdM": 162.4296764,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.RVTY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 113.5622,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.1,
            "take_profit_price": 126.987,
            "target_multiplier": 1.6,
            "technical_strength": 1.22,
            "take_profit_percent": 5
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.100380353894494,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.RVTY",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 3.6889,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.05
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -35.85
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2197
    },
    "kdj": {
      "d": 58.74,
      "j": -12.14,
      "k": 35.12,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 54.97
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 4942940,
      "recentSlope": -1187696,
      "previousSlope": 660950
    },
    "rsi": 43.99,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 132.4107,
      "position": "SAR喺價上",
      "distancePct": 9.48,
      "previousTrend": "下降"
    },
    "ma50": 117.1246,
    "macd": {
      "macd": 2.930951714105305,
      "trend": "中性偏多",
      "signal": 3.780963794282366,
      "histogram": -0.850012080177061
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 124.6846,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.84,
      "score": 4,
      "avgVolume": 1589793,
      "currentVolume": 1343060
    },
    "derived": {
      "ma20": 124.2105,
      "ma50": 117.1246,
      "prevClose": 123.85,
      "avgVolume10": 1801266,
      "avgVolume20": 1589793,
      "changePercent": -2.35,
      "avgVolumeForScore": 1589793
    },
    "ma_cross": {
      "ma20": 124.2105,
      "ma50": 117.1246,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 124.0575,
      "prevMa50": 116.931,
      "spreadPct": 6.05,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 113.9992,
      "upper": 134.4218,
      "position": "中間"
    },
    "rsi_short": 30.31,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.84
    }
  }
}

{
  "close": 120.94,
  "volume": 1343060,
  "changePercent": -2.35
}